Insider Selling: Artiva Biotherapeutics (NASDAQ:ARTV) CEO Sells 3,187 Shares of Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) CEO Fred Aslan sold 3,187 shares of Artiva Biotherapeutics stock in a transaction on Monday, December 15th. The shares were sold at an average price of $6.00, for a total transaction of $19,122.00. Following the completion of the transaction, the chief executive officer owned 1,209,948 shares in the company, valued at approximately $7,259,688. This trade represents a 0.26% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Fred Aslan also recently made the following trade(s):

• On Monday, November 17th, Fred Aslan sold 6,375 shares of Artiva Biotherapeutics stock. The shares were sold at an average price of $3.38, for a total transaction of $21,547.50.
• On Friday, October 17th, Fred Aslan sold 25,500 shares of Artiva Biotherapeutics stock. The shares were sold at an average price of $6.00, for a total transaction of $153,000.00.

Artiva Biotherapeutics Stock Performance

Shares of NASDAQ ARTV traded up $3.00 during midday trading on Monday, reaching $6.30. 47,522,861 shares of the company’s stock were exchanged, compared to its average volume of 117,579. Artiva Biotherapeutics, Inc. has a 52-week low of $1.47 and a 52-week high of $11.55. The business’s fifty day moving average price is $3.70 and its two-hundred day moving average price is $2.91. The stock has a market capitalization of $154.63 million, a PE ratio of -2.44 and a beta of 3.10.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its earnings results on Wednesday, November 12th. The company reported ($0.88) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.04. Analysts predict that Artiva Biotherapeutics, Inc. will post -4.95 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Artiva Biotherapeutics

Several large investors have recently added to or reduced their stakes in the company. Prelude Capital Management LLC bought a new stake in shares of Artiva Biotherapeutics in the 3rd quarter valued at $41,000. Bank of America Corp DE raised its holdings in shares of Artiva Biotherapeutics by 225.8% in the third quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock valued at $46,000 after purchasing an additional 11,190 shares during the last quarter. Ground Swell Capital LLC bought a new stake in Artiva Biotherapeutics during the 2nd quarter worth about $38,000. Y Intercept Hong Kong Ltd acquired a new position in Artiva Biotherapeutics during the second quarter valued at approximately $48,000. Finally, Bridgeway Capital Management LLC bought a new position in shares of Artiva Biotherapeutics in the second quarter valued at $53,000.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on ARTV shares. Wedbush boosted their price objective on Artiva Biotherapeutics from $18.00 to $23.00 and gave the stock an “outperform” rating in a research note on Friday, October 17th. HC Wainwright upped their price target on shares of Artiva Biotherapeutics from $12.00 to $15.00 and gave the company a “buy” rating in a report on Wednesday, November 12th. Jefferies Financial Group upgraded shares of Artiva Biotherapeutics to a “strong-buy” rating in a research report on Tuesday, November 18th. Needham & Company LLC reiterated a “buy” rating and issued a $18.00 target price on shares of Artiva Biotherapeutics in a report on Friday, October 17th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Thursday, October 30th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $19.00.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.